Valeda® Light Delivery System, a breakthrough in treating dry age-related macular degeneration (AMD), has recently received FDA approval, marking a significant advancement in options for AMD patients. Valeda biomodulation therapy is a non-invasive treatment designed to improve retinal function through low-level light therapy (LLLT). By delivering specific wavelengths of light to targeted retinal areas, Valeda enhances cellular function and increases blood flow, potentially slowing AMD progression and improving visual outcomes. What is Valeda Biomodulation Therapy? Valeda uses photobiomodulation, a form of low-intensity light therapy, that stimulates the cells in the retina. The therapy works by enhancing the mitochondrial activity within the retinal cells, which can improve energy production, reduce oxidative stress, and enhance overall cell function. These effects are particularly beneficial for patients with dry AMD, where retinal cells progressively deteriorate. What Patients Should Expect Valeda biomodulation treatment is painless and non-surgical. Patients receive a series of light therapy sessions over a prescribed period. Each session is short, lasting only a few minutes, and requires no downtime. Studies have shown that many patients experience stabilized or improved vision following the treatment, though individual results can vary. This FDA approval represents a milestone in AMD treatment, providing new hope for those seeking to manage this progressive condition.